1323276-66-9

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 50528-73-9 4-benzyloxy-phenyl isocyanate 
• 57260-73-8 N-BOC-1,2-diaminoethane 

Downstream Products

• 1323276-69-2 tert-butyl 2-(3-(4-(3-fluoropropoxy)phenyl)ureido)ethylcarbamate 
• 915287-82-0 [2-[3-(4-(2-fluoro-ethoxy)-phenyl)-ureido]-ethyl]-carbamic acid t-butyl ester 
• 1037412-37-5 1-(2-aminoethyl)-3-[4-(3-fluoropropoxy)-phenyl]-urea 
• 1037411-67-8 (S)-1-(2-(3-(2-cyanophenoxy)-2-hydroxypropylamino)ethyl)-3-(4-(3-fluoropropoxy) phenyl)urea 

Relevant academic research and scientific papers

PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES

A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C8 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; is linear C2-3 alkylene,; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92 SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10) aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or f urther substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3; and R9 is selected from H and a group R8 as hereinbefore defined; n7 and n8 and the sum thereof are independently selected from zero and the whole number integer 1 to 4; processes for the preparation thereof, compositions and uses.

Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.